Posted by Michael Wonder on 08 Aug 2024
Takeda receives European Commission approval for Adzynma (recombinant ADAMTS13) as the first and only recombinant ADAMTS13 replacement therapy for congenital thrombotic thrombocytopenic purpura
7 August 2024 - Approval based on totality of evidence, including results from the first randomised, controlled, open-label, cross-over Phase 3 cTTP trial.
Takeda today announced that the European Commission approved Adzynma (recombinant ADAMTS13) for the treatment of ADAMTS13 deficiency in children and adult patients with congenital thrombotic thrombocytopenic purpura.
